# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Ascendiant Capital analyst Edward Woo maintains NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and raises the price target fro...
HOPE Therapeutics, Inc., a subsidiary of NRx Pharmaceuticals, Inc. (NASDAQ: NRXP),
HOPE Therapeutics, Inc., a wholly-owned subsidiary of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("HOPE," the "Company...
NRX Pharmaceuticals (NASDAQ:NRXP) reported quarterly losses of $(0.75) per share which missed the analyst consensus estimate of...
HC Wainwright & Co. analyst Vernon Bernardino maintains NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy, adjusts target to $19...
FDA response highlights the importance of addressing suicidal depression in adolescents age 9-17Alignment on initial Pediatric ...
Petition for a temporary restraining order brought by Streeterville Capital, LLC seeking injunctive relief to prevent spinoff o...